Prolonged endothelin (ET) receptor signalling causes vasoconstriction and can lead to hypertension, vascular smooth muscle hypertrophy, and hyperplasia. Usually, G protein-coupled receptor signalling is negatively regulated by G protein-coupled receptor kinases (GRKs), preventing prolonged or inappropriate signalling. This study investigated whether GRKs regulate ET receptor contractile signalling in adult Wistar rat mesenteric arterial smooth muscle cells (MSMCs).
Introduction
Endothelin (ET)-1 is a potent vasoconstrictor controlling vascular tone with an established role in vascular smooth muscle hypertrophy 1,2 and hyperplasia, 3, 4 fibrosis and inflammatory responses, leading to vascular remodelling and hypertension. 4, 5 ET-1 plays a crucial role in a number of experimental models of hypertension, 5, 6 and increased plasma ET-1 levels have been reported in hypertensive patients. 7 Endothelins can signal through two receptor subtypes ET A and ET B , however in arterial smooth muscle ET A receptors (ET A R) mediate constrictor responses. 8 ET A Rs couple through Ga q/11 to activate phospholipase C (PLC), generating inositol 1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG), and leading to the release of intracellular Ca 2þ stores and the activation of protein kinase C. 2, 8 ET A R-mediated intracellular Ca 2þ increases underlie a major component of ET-1-induced vasoconstriction. ET-1 also promotes PKC-induced inhibition of voltage-gated K þ channels to further enhance vasoconstriction. 9 Previous studies have shown that antagonizing ET A R signalling can reverse hypertrophy and hypertension in animal models, 10 indicating a potentially important role for ET A R over-activation in the development of vascular disease. Over-stimulation of ET A R signalling clearly has adverse effects on vascular smooth muscle cells, and understanding the mechanisms that regulate Ga q/11 signalling is of potential importance in understanding and treating vascular diseases. Continual or repeated stimulation of receptors by agonists usually leads to reduced responsiveness to further agonist challenge. 11 This process, known as receptor desensitization, has been shown to protect cells from the adverse effects of over-stimulation or inappropriate signalling. Phosphorylation of key serine and/or threonine residues within the third intracellular loop and/or C-terminal tail of the G protein-coupled receptor is thought to be the primary event initiating desensitization and is often mediated by one or more members of a family of seven serine/threonine kinases, the G protein-coupled receptor kinases (GRKs). 11 Phosphorylation by GRKs enhances receptor affinity for the non-visual arrestins 2 and 3, which can sterically suppress further interaction between receptor and G proteins. 12 Although previous studies have shown that recombinantly expressed ET A Rs are phosphorylated and desensitized in a GRK-dependent manner in model cells, such as HEK293 cells, 13 little evidence is currently available to indicate which, if any, GRKs regulate endogenous ET A R signalling in vascular smooth muscle. This is an important issue as recombinant receptors are often regulated very differently to those expressed endogenously. Indeed, a growing number of studies are revealing that precise definition of the GRKs involved in receptor regulation can only be truly defined in a system endogenously expressing the receptor of interest and through manipulation of endogenous GRK populations. 11,14 -16 Here, we have combined confocal imaging techniques and specific inhibition of endogenous GRK isoenzymic activities to examine the interaction between GRKs and the native ET A R population in isolated, cultured mesenteric smooth muscle cells (MSMCs), a widely studied model of systemic resistance arteries. 
Immunocytochemistry
MSMCs were cultured for 72 h before fixation and permeabilization in 100% methanol (10 min at 2208C). GRK expression was identified through addition of specific anti-rabbit polyclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) against GRK2, GRK3, GRK5, and GRK6. Protein expression was visualized with the addition of fluorescein isothiocyanate-conjugated secondary antibodies, before viewing on an Olympus FV500 laser scanning confocal IX70 inverted microscope.
Small interfering RNA knockdown of endogenous GRK2 levels and western blotting
Expression of GRKs and dominant-negative GRKs (see below) was determined using standard immunoblotting protocols as described previously 14 using specific anti-rabbit polyclonal antibodies against GRK2, GRK3, GRK5, and GRK6. MSMCs (1 Â 10 6 ) were transfected with 10 or 100 nM negative-control or anti-GRK2 (5 0 -GCAGGUACCUCCAGAUCUCtt-3 0 ) (Applied Biosystems, UK) small interfering (si)RNAs. Cells were lysed after 48 h and GRK expression assessed by immunoblotting (see above). GRK expression was quantified using the GeneGnome image analysis system (Syngene, Cambridge, UK).
Manipulating cellular GRK activity
GRK2/3 constructs were mutated in both the N-terminal RGS-like domain (D110A) (to prevent binding to Ga q/11 proteins
11
) and the catalytic-domain (K220R) to allow potential receptor/GRK phosphorylation-dependent interactions to be examined. 11, 19 In
MSMCs transfected with D110A,K220R GRK2 or D110A,K220R
GRK3 constructs, normal PLC signalling was unaffected. In contrast, expression of K220R GRK2 or K220R GRK3 markedly attenuated PLC signalling (data not shown), most likely through the previously reported phosphorylation-independent inhibition of Ga q/11 transduction through an interaction with the GRK2/3 RGS-homology (RH) domain. 19 GRK activity was manipulated using the dominant-negative constructs D110A,K220R GRK2, D110A,K220R GRK3, K215R GRK5, or K215R GRK6 (0.5 mg), negative-control plasmid (pcDNA3), or through addition of anti-GRK2, or negative-control siRNAs (10 nM). Cells were transfected using LipofectAMINE2000 (Invitrogen, Paisley, UK) according to the manufacturer's instructions. (0.5 mg), and anti-GRK2 siRNA as above. After 48 h, cells were loaded with Fura-Red (3 mM) for 50 min before commencing imaging experiments.
Data and statistical analysis
Data presented are from cells obtained from at least three separate preparations and are expressed as means + SEM. Data were analysed using one-way ANOVA as indicated, with appropriate post hoc testing (GraphPad Prism, San Diego, CA, USA). ] i response ( Figure 1B) . The reduction in the R2/R1 ratio can be interpreted as an indicator of ET A R desensitization. 14, 19 Increasing the washout period provided evidence of a slow and incomplete re-sensitization, with R2 for the IP 3 response still 70% less than R1 after 60 min ( Figure 1C , D).
Results
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GRK expression in MSMCs
Immnuoblotting data showed that GRKs 2, 5, 6 are expressed in rat MSMCs, however, in agreement with the previous findings 16 we were unable to detect GRK3 expression (see Supplementary material online, Figure S1 ). Immunocytochemical evidence highlights an anticipated cytoplasmic distribution of GRK2 ( Figure 6A ), whereas GRK5 expression appears to be primarily nuclear ( Figure 6B and C).
Effects of inhibiting endogenous GRK activities on ET A R signalling
To determine which endogenous GRKs modulate ET A R signalling, we inhibited individual GRK isoenzymes by over-expressing catalytically inactive, dominant-negative GRK mutants. This approach has been successfully used in a number of studies to bring about highly selective GRK isoenzymic inhibition. 14, 15 MSMCs were co-transfected with eGFP-PH (0.5 mg) and pcDNA3 (control), D110A,K220R GRK2, 19 D110A,K220R GRK3, K215R GRK5 or K215R GRK6
(0.5 mg). 21 MSMCs transfected with dominant-negative GRKs were subjected to the standard desensitization protocol (R1/R2) with 10 min washout between ET-1 additions. Control experiments, co-transfecting monomeric red fluorescent protein and eGFP-tagged dominant-negative GRKs indicated .90% co-transfection of cells (data not shown). In MSMCs transfected with pcDNA3 (Figure 2A reductions in ET A R responsiveness to those observed in untransfected cells. However, in the presence of D110A,K220R GRK2, the R2 IP 3 response was decreased by 40% relative to R1, whereas the reduction in R2 for the ET-1-stimulated Ca 2þ signal was almost completely ablated (Figure 2A , C, G). These data indicate that inhibition of endogenous GRK2 activity results in a highly significant attenuation of ET-1-induced ET A R desensitization.
To confirm and extend our findings, MSMCs were transfected with siRNAs designed to target GRK2. Optimal depletion of endogenous GRK2 was achieved 48 h after siRNA transfection at concentrations of siRNA of !10 nM ( Figure 3A, B) . This effect was shown to be GRK2-specific as the anti-GRK2-siRNA did not affect GRK6 expression ( Figure 3A, B) . A negative-control siRNA had no effect on either GRK2 or GRK6 expression ( Figure 3B ). In addition, we co-transfected MSMCs with eGFP (0.5 mg) and either negative-control or anti-GRK2 siRNAs (10 or 100 nM) and 48 h later GRK2 expression was determined immunocytochemically. Our previous work indicates that co-transfection rates are .90%; therefore, we have assumed that all eGFP-expressing cells were also transfected with siRNA constructs. When compared with non-eGFP-expressing cells, the presence of eGFP and negative-control siRNA did not affect GRK2 expression (data not shown), however, transfection with anti-GRK2 siRNA caused a marked reduction (75%) in GRK2 immunoreactivity ( Figure 3C, D) , whereas GRK5 and 6 expression was unaffected ( Figure 3D) .
To examine the effect of siRNA-mediated GRK2 knockdown on ET A R desensitization, MSMCs were co-transfected with eGFP-PH (0.5 mg) and negative-control (10 nM) or anti-GRK2 (10 nM) siRNAs and subjected to the standard R1/R2 desensitization protocol. In the presence of negative-control siRNA, R2 responses were decreased by !80% for eGFP-PH and by !60% for [Ca 2þ ] i signals compared with R1, consistent with the degree of receptor desensitization observed in untransfected cells ( Figure 4A, B, D) . In contrast, in cells transfected with anti-GRK2 siRNA, R2 and R1 responses were similar to those previously seen in D110A,K220R
GRK2-transfected MSMCs, with a 50% decrease in eGFP-PH and 30% decrease in Ca 2þ signals ( Figure 4A , C, D).
To assess whether quantitatively similar effects of manipulating cellular GRK2 are seen with respect to the DAG/PKC arm of the ET A R signalling pathway, we have assessed ET-1-stimulated translocation of the Ca 2þ and DAG-sensitive PKCa and DAG-sensitive PKC1 isoenzymes. Applying the standard desensitization protocol to eGFP-PKCa-( Figure 5A , C) or eGFP-PKC1 ( Figure 5B , C)-transfected MSMCs showed that a significantly greater recovery with respect to PKC recruitment responses was also observed when cellular GRK2 levels were selectively diminished.
ET-1-stimulated recruitment of endogenous GRKs
To investigate further GRK2-mediated regulation of ET A R signalling, we examined the redistribution of this GRK isoenzyme following ET-1 addition. The MSMCs were treated with ET-1 (50 nM) for 3 min, after which cells were fixed and processed to allow immunocytochemical detection of GRKs. Confocal images show GRK2 recruitment to the plasma membrane following ET-1 exposure ( Figure 6A ). The predominantly nuclear localization of GRK5 was unaltered following ET-1 challenge ( Figure 6B ), whereas addition of the Ca 2þ -ionophore ionomycin promoted GRK6 (F). ET A R desensitization was determined as the relative change in R2 response compared with R1 for both eGFP-PH (black traces) and Fura-Red (broken traces). Cumulative data (G) are expressed as means + SEM for the percentage change in R2 relative to R1; n ¼ 7 -17 cells for each time-point, from at least eight separate experiments from three or more different animals. Statistical significance is indicated as **P , 0.01 vs. pcDNA3 (one-way ANOVA and Dunnett's post hoc test). Figure 6C ). We were unable to detect recruitment of GRK3 (data not shown), and due to its 'constitutive' plasma membrane localization GRK6 11 was not studied here.
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GRK5 translocation to the cytoplasm (
Does protein kinase C have a role in ET A R desensitization
ET A R activation can recruit PKC isoenzymes to the plasma membrane 20 raising the possibility that PKCs may also be involved in ET A R regulation. To assess whether PKC plays a role in ET A R desensitization, we used two complementary approaches: (i) preincubation of MSMCs with staurosporine (1 mM) or dimethyl sulphoxide (vehicle control) for 10 min prior to and throughout the standard R1/R2 desensitization protocol and (ii) downregulation of PKC isoenzymes by a 24 h pre-treatment with phorbol 12,13-dibutyrate (PDBu, 1 mM). Neither acute treatment with staurosporine (see Supplementary material online, Figure  S2C , E) nor chronic phorbol ester treatment (see Supplementary material online, Figure S2E ) had any effect on ET-1-induced ET A R desensitization. In addition, the magnitude of effect on ET A R desensitization caused by the siRNA GRK2 knockdown strategy was unaltered in MSMCs additionally treated with either staurosporine or chronic PDBu (see Supplementary material online, Figure S2D , E).
Discussion
ET-1, a potent vasoconstrictor important in the regulation of vascular tone, has also been reported to promote vascular hypertrophy and hyperplasia. 1, 3, 4 In vascular smooth muscle, ET A R has been shown to be the dominant receptor subtype mediating ET-1 smooth muscle contraction. 8 In agreement, we find that ET-1 23 and most probably ET A R down-regulation. 24 Data from studies in recombinant cell systems suggest that GRKs are able to regulate ET A R signalling. 13 Indeed, when expressed in HEK293 cells, ET A R rapidly desensitized, and Figure 4 Depletion of endogenous GRK2 inhibits ET A R desensitization. MSMCs were co-transfected with 0.5 mg eGFP-PH and either negative-control or anti-GRK2 (10 nM) siRNAs. Cells were loaded with Fura-Red and subjected to the standard R1/R2 desensitization protocol (see Methods). (A) Representative images of changes in IP 3 and Ca 2þ in MSMCs expressing either control siRNA or anti-GRK2 siRNA at both the R1 and R2 stimulation points are shown. Representative traces from single cells transfected with control siRNA (B) or anti-GRK2 siRNA (C). ET A R desensitization was determined as the relative change in R2 response compared with R1 for both eGFP-PH (black traces) and Fura-Red (broken traces). Cumulative data (D) show means + SEM from 7 -9 cells from four or more animals. Statistical significance is indicated as **P , 0.01; ***P , 0.001 (one-way ANOVA, unpaired t-test).
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phosphorylation of the receptor was enhanced by recombinant over-expression of GRKs 2, 5, or 6. 13 In addition, over-expression of recombinant GRK2 and GRK3 increased ET A R phosphorylation in CHO cells. 25 Together these and other studies suggest that
GRKs are able to cause ET A R phosphorylation, however, such studies are not necessarily predictive of how/if the receptor will be regulated by specific GRK isoenzymes in native ET A R expression systems. Therefore, a key objective here was to delineate for the first time the role that endogenous GRK isoenzymes play in ET A R regulation in resistance artery smooth muscle. Owing to the lack of effective and specific pharmacological GRK inhibitors, we applied previously validated molecular approaches to disrupt or decrease activity of specific endogenous GRK isoenzymes. Initially, we used dominant-negative (kinase-dead) GRK mutants to disrupt ET A R/GRK isoenzyme-specific interactions in an attempt to attenuate or prevent the reduction in ET A R responsiveness observed on re-addition of ET-1. The D110A,K220R
GRK2 construct, GRK2 regulates endothelin signalling which is mutated to prevent both kinase activity and Ga q/ 11 -binding, 19 markedly attenuated ET A R desensitization. In contrast, over-expression of D110A,K220R GRK3, K215R GRK5, or K215R GRK6 mutants had no effect on the extent or time course of recovery of ET A R responsiveness to ET-1. A potential criticism of the dominant-negative GRK overexpression approach is the possibility of 'off-target' effects or lack of sufficient specificity towards the GRK isoenzyme being targeted. This clearly was not the case here given the marked contrast between effects of the GRK2 and 3 constructs, nevertheless, to provide a complementary experimental approach we used specific siRNAs to deplete (by !75%) endogenous GRKs in MSMCs. In agreement with the D110A,K220R GRK2 experiments, siRNA-induced depletion of GRK2 also markedly attenuated the ET-1-induced ET A R desensitization with respect to IP 3 , Ca 2þ , and DAG/PKC signal readouts. Furthermore, redistribution of endogenous GRK2 from the cytoplasm to the membrane could be detected after a brief ET-1 stimulation, most likely indicating recruitment to agonist-occupied ET A Rs. Interestingly, despite previous reports of the plasma membrane association of GRK5, this isoenzyme is predominantly located within the nuclei of MSMCs. Nuclear accumulation of GRK5 has been reported previously in cardiomyocytes, 26 presumably as a consequence of its nuclear localization sequence.
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Our study also represents a first report of the nuclear GRK5 localization in MSMCs, although the significance of this finding for GPCR signalling and vascular physiology remains to be established. Collectively, these data indicate that GRK2 is the key endogenous GRK subtype initiating ET A R desensitization in MSMCs, with either GRK2 knockdown or disruption of the normal GRK2-ET A R interactions causing an 50% attenuation of ET A R desensitization. This partial blockade may arise, because the experimental strategy is incompletely effective, or may indicate that other, so far undefined mechanisms are involved in regulating ET A R responsiveness. In MSMCs, ET A R activation is known to recruit several PKC isoenzymes 9, 20 and PKC activation is known to phosphorylate ET A R, at least in a HEK293 cell background, 13 suggesting a potential role for this protein kinase family in ET A R desensitization. In addition, PKCs are also known to phosphorylate GRK2 enhancing its membrane recruitment 28 and ability to desensitize GPCRs. 29 Unfortunately, most of the available PKC inhibitors are fluorescent molecules precluding their use with the translocating, fluorescent biosensors. Consequently, we used the complementary approaches of inhibiting PKC activity with either the broadspecificity PKC inhibitor staurosporine, or down-regulating conventional and novel PKC isoenzymes through chronic treatment of MSMCs with the phorbol ester, PDBu. Neither manipulation of MSMCs suggested that PKCs play a role in the ET A R desensitization process nor alter the ability of GRK2 to exert its effect on the ET A R. Nevertheless, it remains a possibility that PKC-mediated ET A R phosphorylation may have as yet undefined roles in directing the signalling outputs of this receptor subtype (e.g. ET-1-mediated inhibition of K þ channels to alter vasoconstrictor responses 9, 17 ). Nonetheless, since GRK2 inhibition appears only partially to prevent ET A R desensitization, it is possible that other mechanisms are involved, perhaps involving more distal regulatory processes such as b-arrestin binding, 25 receptor internalization and/or receptor down-regulation. 24 Accumulating evidence indicates that GRKs play an important role in the pathogenesis of vascular disease. In experimental systems, adenovirus-mediated over-expression of GRK2 in cultured rabbit aortic smooth muscle cells attenuated ET-1-induced proliferation, 30 whereas a two-to three-fold over-expression of GRK2 in vascular smooth muscle significantly reduced functional (increases in mean arterial pressure) responses to angiotensin II in mice. 31 These findings suggest a protective role for GRK2 expression, presumably by enhancing the desensitization of these pro-hypertensive signals. However, in apparent contradiction to these findings, GRK2 expression has been reported to be enhanced in both hypertensive patients 32 and rat models of hypertension. A possible explanation for this discrepancy is that overexpression of GRK2 not only attenuates vasoconstrictor (e.g. angiotensin II) signalling, but also vasodilator signalling. Specifically, signalling through the b 2 -adrenoceptor is substantially reduced in vascular smooth muscle over-expressing GRK2. 31 In addition, since GRK2 is able to suppress Ga q -signalling through its Nterminal RGS-like domain, 11 it is conceivable that elevated GRK2 expression is initially an adaptive response to over-stimulation of Ga q -signalling pathways, preventing inappropriate vasoconstriction and resultant hypertension. 33 It is therefore clear that GRK2 is linked to hypertensive adaptations, but its exact role in the development of hypertension merits further investigation. In summary, here we have provided important new evidence highlighting the role played by GRK2 in regulating ET-1/ET A R/Ga q -mediated vasoconstriction and suggest that this GRK isoenzyme might protect against ET-1-induced vascular dysfunction.
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